Abivax SA - American Depositary Shares (NQ:ABVX)

91.73 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Via The Motley Fool

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗

December 09, 2025

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.

Via The Motley Fool

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗

December 09, 2025

A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Outlook For Abivax ↗

August 08, 2025

Via Benzinga

6 Healthcare Stocks With Strong Upward Momentum ↗

November 18, 2025

Via Benzinga

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗

November 17, 2025

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Via The Motley Fool

Topics Regulatory Compliance

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗

November 17, 2025

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Via The Motley Fool

This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 06, 2025

Via Benzinga

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

November 03, 2025

From Abivax

Via GlobeNewswire

Tilray Brands Posts Upbeat Results, Joins Byrna Technologies, Delta Air Lines And Other Big Stocks Moving Higher On Thursday ↗

October 09, 2025

Via Benzinga

AMD To Rally More Than 47%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 07, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 06, 2025

Via Benzinga

Why Is Abivax Stock Trading Higher On Monday? ↗

October 06, 2025

Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no new safety concerns.

Via Benzinga

Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease ↗

October 06, 2025

The company is working on a treatment for a form of inflammatory bowel disease, a highly watched disease area.

Via Investor's Business Daily

Topics Government

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

October 06, 2025

From Abivax

Via GlobeNewswire

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

October 05, 2025

From Abivax

Via GlobeNewswire

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

September 29, 2025

From Abivax

Via GlobeNewswire

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

September 23, 2025

From Abivax

Via GlobeNewswire

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

September 12, 2025

From Abivax

Via GlobeNewswire

RH Posts Downbeat Results, Joins Frequency Electronics, Tronox And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

September 12, 2025

Via Benzinga

Abivax Presents First Half 2025 Financial Results

September 08, 2025

From Abivax

Via GlobeNewswire

Market Movers: Robinhood, AppLovin Surge into S&P 500 Amidst Crucial Earnings Season

September 08, 2025

The financial markets are abuzz with significant corporate developments as several key companies navigate pivotal moments, ranging from prestigious S&P index inclusions to critical quarterly earnings...

Via MarketMinute

Topics Artificial Intelligence ETFs Retirement

This Stock Is Up by 800% This Year -- but Is It a Buy? ↗

July 31, 2025

This little-known biotech might still deliver strong returns.

Via The Motley Fool

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Abivax Announces Closing of $747.5 Million Public Offering

July 28, 2025

From Abivax

Via GlobeNewswire

Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

July 25, 2025

From Abivax

Via GlobeNewswire

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

July 24, 2025

From Abivax

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.